↓ Skip to main content

Serum tumor markers in pediatric osteosarcoma: a summary review

Overview of attention for article published in Clinical Sarcoma Research, March 2012
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#43 of 104)
  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 X user
googleplus
1 Google+ user

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
51 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Serum tumor markers in pediatric osteosarcoma: a summary review
Published in
Clinical Sarcoma Research, March 2012
DOI 10.1186/2045-3329-2-9
Pubmed ID
Authors

Yulia A Savitskaya, Genaro Rico-Martínez, Luis Miguel Linares-González, Ernesto Andrés Delgado-Cedillo, René Téllez-Gastelum, Alfonso Benito Alfaro-Rodríguez, Antonio Redón-Tavera, José Clemente Ibarra-Ponce de León

Abstract

Osteosarcoma is the most common primary high-grade bone tumor in both adolescents and children. Early tumor detection is key to ensuring effective treatment. Serum marker discovery and validation for pediatric osteosarcoma has accelerated in recent years, coincident with an evolving understanding of molecules and their complex interactions, and the compelling need for improved pediatric osteosarcoma outcome measures in clinical trials. This review gives a short overview of serological markers for pediatric osteosarcoma, and highlights advances in pediatric osteosarcoma-related marker research within the past year. Studies in the past year involving serum markers in patients with pediatric osteosarcoma can be assigned to one of four categories, i.e., new approaches and new markers, exploratory studies in specialized disease subsets, large cross-sectional validation studies, and longitudinal studies, with and without an intervention.Most of the studies have examined the association of a serum marker with some aspect of the natural history of pediatric osteosarcoma. As illustrated by the many studies reviewed, several serum markers are emerging that show a credible association with disease modification. The expanding pool of informative osteosarcoma-related markers is expected to impact development of therapeutics for pediatric osteosarcoma positively and, it is hoped, ultimately clinical care. Combinations of serum markers of natural immunity, thyroid hormone homeostasis, and bone tumorigenesis may be undertaken together in patients with pediatric osteosarcoma. These serum markers in combination may do better. The potential effect of an intrinsic dynamic balance of tumor angiogenesis residing within a single hormone (tri-iodothyronine) is an attractive concept for regulation of vascularization in pediatric osteosarcoma.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Unknown 50 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 22%
Student > Master 9 18%
Student > Postgraduate 6 12%
Student > Bachelor 4 8%
Student > Ph. D. Student 4 8%
Other 9 18%
Unknown 8 16%
Readers by discipline Count As %
Medicine and Dentistry 30 59%
Biochemistry, Genetics and Molecular Biology 5 10%
Agricultural and Biological Sciences 3 6%
Veterinary Science and Veterinary Medicine 1 2%
Sports and Recreations 1 2%
Other 1 2%
Unknown 10 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 May 2012.
All research outputs
#13,360,458
of 22,663,969 outputs
Outputs from Clinical Sarcoma Research
#43
of 104 outputs
Outputs of similar age
#89,524
of 160,528 outputs
Outputs of similar age from Clinical Sarcoma Research
#1
of 2 outputs
Altmetric has tracked 22,663,969 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 104 research outputs from this source. They receive a mean Attention Score of 3.5. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 160,528 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them